Compare Quest Diagnostics Inc (DGX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Prudential PLC — how do they compare? Quest Diagnostics Inc trades at $230.93 (market cap $25.48B), while Prudential PLC trades at $23.91 (market cap $28.84B). The key difference: Quest Diagnostics Inc and Prudential PLC are close in size by market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Prudential PLC for 119 Days on average.
| DGX | PUK | |
|---|---|---|
Market Cap | $25.48B | $28.84B |
Volume | 941,866 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $247.45 | $33.61 |
52-Week Low | $173.49 | $23.54 |
Typical Hold Time | 56 Days | 119 Days |
Enterprise Value | $31.23B | $28.38B |
Dividend Yield | 1.49% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
